A phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of simtuzumab (GS-6624) combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

被引：0
|
作者：
Benson, Al Bowen
Thai, Zung
Hawkins, Michael J.
Werner, Douglas
Dong, Hua
Lee, Claudia
Bendell, Johanna C.
机构：
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Gilead Sci Inc, Foster City, CA 94404 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4149
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma
    Benson, Al B., III
    Wainberg, Zev A.
    Hecht, J. Randolph
    Vyushkov, Dmitry
    Dong, Hua
    Bendell, Johanna
    Kudrik, Fred
    ONCOLOGIST, 2017, 22 (03): : 241 - +
  • [2] A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma.
    Hecht, J. Randolph
    Bendell, Johanna C.
    Vyushkov, Dmitry
    Bencardino, Katia
    Verma, Udit N.
    Yang, Yingsi
    Thai, Dung Luong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients
    Hong, Jung Yong
    Nam, Eun Mi
    Lee, Jeeyun
    Park, Joon Oh
    Lee, Sang-Cheol
    Song, Seo-Young
    Choi, Seong Ho
    Heo, Jin Seok
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 125 - 130
  • [4] Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients
    Jung Yong Hong
    Eun Mi Nam
    Jeeyun Lee
    Joon Oh Park
    Sang-Cheol Lee
    Seo-Young Song
    Seong Ho Choi
    Jin Seok Heo
    Se Hoon Park
    Ho Yeong Lim
    Won Ki Kang
    Young Suk Park
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 125 - 130
  • [5] A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
    Bendell, Johanna C.
    Starodub, Alexander
    Huang, Xi
    Maltzman, Julia D.
    Wainberg, Zev A.
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma
    Hecht, J. Randolph
    Benson, Al B., III
    Vyushkov, Dmitry
    Yang, Yingsi
    Bendell, Johanna
    Verma, Udit
    ONCOLOGIST, 2017, 22 (03): : 243 - +
  • [7] A double-blinded, placebo-controlled, randomized study to evaluate the efficacy of perioperative dextromethorphan compared to placebo for the treatment of postoperative pain: a study protocol
    Ian A. Jones
    Amit S. Piple
    Pui Yuk Yan
    Donald B. Longjohn
    Paul K. Gilbert
    Jay R. Lieberman
    Gligor V. Gucev
    Daniel A. Oakes
    Christina E. Ratto
    Alexander B. Christ
    Nathanael D. Heckmann
    Trials, 24
  • [8] A double-blinded, placebo-controlled, randomized study to evaluate the efficacy of perioperative dextromethorphan compared to placebo for the treatment of postoperative pain: a study protocol
    Jones, Ian A. A.
    Piple, Amit S. S.
    Yan, Pui Yuk
    Longjohn, Donald B. B.
    Gilbert, Paul K. K.
    Lieberman, Jay R. R.
    Gucev, Gligor V. V.
    Oakes, Daniel A. A.
    Ratto, Christina E. E.
    Christ, Alexander B. B.
    Heckmann, Nathanael D. D.
    TRIALS, 2023, 24 (01)
  • [9] Safety and Efficacy of Ivermectin for the Prevention and Treatment of COVID-19: A Double-Blinded Randomized Placebo-Controlled Study
    Angkasekwinai, Nasikarn
    Rattanaumpawan, Pinyo
    Chayakulkeeree, Methee
    Phoompoung, Pakpoom
    Koomanachai, Pornpan
    Chantarasut, Sorawit
    Wangchinda, Walaiporn
    Srinonprasert, Varalak
    Thamlikitkul, Visanu
    ANTIBIOTICS-BASEL, 2022, 11 (06):
  • [10] Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.
    Van Cutsem, Eric
    Hidalgo, Manuel
    Bazin, Igor
    Canon, Jean-Luc
    Poddubskaya, Elena
    Manojlovic, Nebojsa
    Milella, Michele
    Radenkovic, Dejan
    Verslype, Chris
    Guo, Wei
    Damstrup, Lars
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345